Crosslinked hyaluronic acid-collagen gels for improving tissue graft viability and soft tissue augmentation

Patent metadata

Field	Value
Publication number	US-9662422-B2
Application number	US-201414535033-A
Country	US
Kind code	B2
Filing date	Nov 6, 2014
Priority date	Sep 6, 2011
Publication date	May 30, 2017
Grant date	May 30, 2017

Abstract

Hydrogels comprising a macromolecular matrix and water may be used to augment soft tissue of a human being, promote or support cell or tissue viability or proliferation, create space in tissue, and for other purposes. A macromolecular matrix may comprise a hyaluronic acid component crosslinked to a collagen component.

First claim

What is claimed is:

1. A method of treating a soft tissue defect in a subject, the method comprising injecting a dermal filler composition into the subject's skin; wherein the composition comprises:
(i) a hydrogel comprising:
(a) water; and
(b) a crosslinked macromolecular matrix comprising hyaluronic acid crosslinked to collagen via a plurality of crosslink units, wherein at least a portion of the crosslink units comprise an amide bond, and wherein the crosslinked macromolecular matrix has a weight ratio of the hyaluronic acid to the collagen of 1:1 to 7:1;

wherein said hydrogel has a hyaluronic acid concentration of 6 mg/mL to 21 mg/mL, a collagen concentration of 3 mg/mL to 12 mg/mL, and a storage modulus value of between 850 Pa and 5,000 Pa; and
(ii) a cellular component comprising cells obtained from adipose tissue;

wherein the composition has a fat:hydrogel weight ratio of 1:1 to 5:1; and
wherein the injection results in an increase in soft tissue volume and an increase in the volume retention, thereby treating the defect.

2. The method of claim 1 , wherein the hyaluronic acid is crosslinked to the collagen using a coupling agent, and wherein the coupling agent is not part of the crosslink unit.

3. The method of claim 1 , wherein the crosslinked macromolecular matrix has a weight ratio of the hyaluronic acid to the collagen of 1:1 to 2:1.

4. The method of claim 1 , wherein the hydrogel has a collagen concentration of greater than or equal to 6 mq/mL.

5. The method of claim 1 , wherein the hydrogel has a hyaluronic acid concentration of at least 9 mg/mL.

6. The method of claim 1 , wherein the hydrogel has a storage modulus value of between 1,000 Pa and 4,000 Pa.

7. The method of claim 1 , wherein the cellular component comprises adipocytes, adipose-derived stem cells, stromal vascular fraction cells, or a combination thereof.

8. The method of claim 1 , wherein the adipose tissue is human adipose tissue.

9. The method of claim 8 , wherein the adipose tissue is a lipoaspirate.

10. The method of claim 1 , wherein the adipose tissue comprises stem cells, progenitor cells, precursor cells or a combination thereof.

11. The method of claim 1 , wherein the hyaluronic acid is crosslinked to the collagen using hyaluronic acid having a molecular weight of 1,000,000 to 5,000,000 daltons.

12. The method of claim 1 , wherein the defect is a wrinkle.

13. The method of claim 1 , wherein the increase in the volume retention is a fat graft volume retention.

14. The method of claim 1 , wherein the hydrogel has a collagen concentration of 6 mg/mL, 8 mg/mL or 12 mg/mL.

15. The method of claim 1 , wherein the hydrogel has a hyaluronic acid concentration of 12 mg/mL and a collagen concentration of 6 mg/mL; a hyaluronic acid concentration of 12 mg/mL and a collagen concentration of 12 mg/mL; or a hyaluronic acid concentration of 16 mg/mL and a collagen concentration of 8 mg/mL.

16. The method of claim 1 , wherein the hyaluronic acid is crosslinked to the collagen using hyaluronic acid having a molecular weight of 1,000,000 daltons to 3,000,000 daltons.

17. The method of claim 1 , wherein the hydrogel has a hyaluronic acid concentration of at least 9 mg/mL and a collagen concentration of greater than or equal to 6 mg/mL.

18. The method of claim 1 , wherein the composition is injected intradermally.

19. The method of claim 1 , wherein the composition is injected subcutaneously.

Assignees

• Allergan Inc

Inventors

• Pollock Jacob F
• Kokai Lauren E
• Cui Cunqi
• Yu Xiaojie
• Van Epps Dennis E
• Messina Darin J

Classifications

• A61L2400/06

  Flowable or injectable implant compositions · CPC title

• A61L2430/34

  for soft tissue reconstruction · CPC title

• A61Q19/08

  Anti-ageing preparations · CPC title

• A61L27/3604

  characterised by the human or animal origin of the biological material, e.g. hair, fascia, fish scales, silk, shellac, pericardium, pleura, renal tissue, amniotic membrane, parenchymal tissue, fetal tissue, muscle tissue, fat tissue, enamel · CPC title

• A61L27/58

  Materials at least partially resorbable by the body · CPC title